SynthesisFrontiers in pharmacology2026
Efficacy and safety of the JAK1 inhibitor abrocitinib for moderate-to-severe atopic dermatitis: a systematic review and meta-analysis.
Bobiao Ning et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.